Highlights Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Delayed Hong Kong S.E. Other stock markets 23:59:40 2024-06-25 EDT			5-day change	1st Jan Change
25.3 ^HKD	0.00%		-4.35%	-7.33%

06-21	Ascentage Pharma Group Completes $75 Million Share Subscription Deal with Takeda International	MT
06-20	Ascentage Pharma Group International announced that it has received $74.999999 million in funding from Takeda International - Uk Branch	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ascentage Pharma Group Completes $75 Million Share Subscription Deal with Takeda International	06-21	MT
Ascentage Pharma Announces Updated Results from Three Studies of Olverembatinib	06-17	CI
Ascentage Pharma Global Registrational Phase III Study of Olverembatinib for the Treatment of Patients with SDH-Deficient Gist Approved by the China CDE	06-10	CI
Ascentage Pharma Releases Updated Clinical Data of olverembatinib in SDH-Deficient GIST, Including a CBR of 92.3%	06-04	CI
Ascentage Pharma Releases Updated Data Showing Promising Efficacy and Safety of Lisaftoclax in Patients with WM	06-04	CI
Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC	06-01	CI
Ascentage Pharma to Present Four Studies on Anti-Cancer Drugs at US Oncology Meet; Shares Fall 4%	05-23	MT
Ascentage Pharma Releases Latest Results from Multiple Clinical Studies of Its Lead Drug Candidates in 2024 American Society of Clinical Oncology Annual Meeting	05-23	CI
Ascentage Pharma to Present Four Studies at US Oncology Meet	04-25	MT
Ascentage Pharma Chairman Boosts Stake in Firm	04-09	MT
Ascentage Pharma Group Directors Acquire Company Shares	04-03	MT
Ascentage Pharma Widens Loss by Nearly 5% in 2023	03-28	MT
Ascentage Pharma Group International Reports Earnings Results for the Full Year Ended December 31, 2023	03-27	CI
Ascentage Pharma to Present Three Preclinical Studies at 2024 American Association of Cancer Research Annual Meeting	03-05	CI
Ascentage Pharma Receives Clearance from the US Food and Drug Administration to Initiate Global Registrational Phase III Trial of Olverembatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia	02-13	CI
Ascentage Pharma Announces Olverembatinib Included in Newest Guidelines on Chronic Myeloid Leukemia Management from the National Comprehensive Cancer Network	01-16	CI
Ascentage Pharma Group International Presents Preliminary Results from A Phase II Study of Novel Drug Candidate, Olverembatinib	12-14	CI
Ascentage Pharma Group International Releases the First Dataset of BCL-2 Inhibitor Lisaftoclax in Patients with R/R Mm, Demonstrating Encouraging ORR and VGPR	12-10	CI
Ascentage Pharma Announces the Launch of Olverembatinib in Newly Approved Indication and the Dispatch of First Batch for the New Indication	11-24	CI
China Approves Ascentage Pharma's Chronic-Phase Chronic Myeloid Leukemia Treatment	11-19	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ascentage Pharma Group International

Equities

6855

KYG0519B1023

Highlights

Filters